Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders., N Engl J Med, 352, 1779, 10.1056/NEJMoa051113 Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis., Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023 James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera., Nature, 434, 1144, 10.1038/nature03546 Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders., Lancet, 365, 1054, 10.1016/S0140-6736(05)71142-9 Kralovics, 2006, Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders., Blood, 108, 1377, 10.1182/blood-2005-11-009605 Schaub, 2010, Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms., Blood, 115, 2003, 10.1182/blood-2009-09-245381 Schaub, 2009, Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the pre-disposing mutations for JAK2-V617F., Blood, 10.1182/blood-2008-07-167056 Delhommeau, 2009, Mutation in TET2 in myeloid cancers., N Engl J Med, 360, 2289, 10.1056/NEJMoa0810069 Abdel-Wahab, 2011, DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms., Leukemia, 25, 1219, 10.1038/leu.2011.82 Carbuccia, 2009, Mutations of ASXL1 gene in myeloproliferative neoplasms., Leukemia, 23, 2183, 10.1038/leu.2009.141 Ernst, 2010, Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders., Nat Genet, 42, 722, 10.1038/ng.621 Vainchenker, 2011, New mutations and pathogenesis of myeloproliferative neoplasms., Blood, 118, 1723, 10.1182/blood-2011-02-292102 Klampfl, 2013, Somatic mutations of calreticulin in myeloproliferative neoplasms., N Engl J Med, 369, 2379, 10.1056/NEJMoa1311347 Nangalia, 2013, Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2., N Engl J Med, 369, 2391, 10.1056/NEJMoa1312542 Tenedini, Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms [published online ahead of print October 22, 2013]., Leukemia Abdel-Wahab, 2010, Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias., Cancer Res, 70, 447, 10.1158/0008-5472.CAN-09-3783 Harutyunyan, 2011, p53 lesions in leukemic transformation., N Engl J Med, 364, 488, 10.1056/NEJMc1012718 Pardanani, 2010, LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations., Leukemia, 24, 1713, 10.1038/leu.2010.163 Pardanani, 2010, IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms., Leukemia, 24, 1146, 10.1038/leu.2010.77 Vannucchi, 2013, Mutations and prognosis in primary myelofibrosis., Leukemia, 27, 1861, 10.1038/leu.2013.119 Vardiman, 2009, The 2008 revision of the World Heatlh Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes., Blood, 10.1182/blood-2009-03-209262 Jutzi, 2013, MPN patients harbor recurrent truncating mutations in transcription factor NF-E2., J Exp Med, 210, 1003, 10.1084/jem.20120521 Thoennissen, 2011, Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN., Am J Hematol, 86, 703, 10.1002/ajh.22069 Jones, 2009, JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms., Nat Genet, 41, 446, 10.1038/ng.334 Jones, 2013, Inherited predisposition to myeloproliferative neoplasms., Ther Adv Hematol, 4, 237, 10.1177/2040620713489144 Marty, 2013, A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression., Leukemia, 27, 2187, 10.1038/leu.2013.102 Plo, 2008, JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders., Blood, 112, 1402, 10.1182/blood-2008-01-134114 Li, 2010, JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia., Blood, 116, 1528, 10.1182/blood-2009-12-259747 Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes., Nature, 499, 214, 10.1038/nature12213 Papaemmanuil, 2013, Clinical and biological implications of driver mutations in myelodysplastic syndromes., Blood, 122, 3616, 10.1182/blood-2013-08-518886 Patel, 2012, Prognostic relevance of integrated genetic profiling in acute myeloid leukemia., N Engl J Med, 366, 1079, 10.1056/NEJMoa1112304 Tefferi, 2009, TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis., Leukemia, 23, 905, 10.1038/leu.2009.47 Jädersten, 2011, TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression., J Clin Oncol, 29, 1971, 10.1200/JCO.2010.31.8576 Zenz, 2010, TP53 mutation and survival in chronic lymphocytic leukemia., J Clin Oncol, 28, 4473, 10.1200/JCO.2009.27.8762 Busque, 2012, Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis., Nat Genet, 44, 1179, 10.1038/ng.2413